Loading …

428 Pharma develops a formulation of the worlds first long-acting injectable (LAI) for prevention of relapse in MDD with a potential time to market in 2028. 428 Pharma pursues a PK-only pathway under FDA 505(b)(2) development with LOE until 2046.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.